Rep. Kevin Hern Sells Off Shares of Medtronic PLC (NYSE:MDT)

Posted by Jeff Wilder on Sep 3rd, 2026

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Medtronic PLC (NYSE:MDT). In a filing disclosed on September 01st, the Representative disclosed that they had sold between $15,001 and $50,000 in Medtronic stock on August 24th. The trade occurred in the Representative’s “HERN FAMILY FOUNDATION” account.

Representative Kevin Hern also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 8/24/2026.
Sold $50,001 – $100,000 in shares of Home Depot (NYSE:HD) on 8/24/2026.
Sold $50,001 – $100,000 in shares of Procter & Gamble (NYSE:PG) on 8/24/2026.
Sold $1,001 – $15,000 in shares of Lowe’s Companies (NYSE:LOW) on 8/24/2026.
Sold $15,001 – $50,000 in shares of Microsoft (NASDAQ:MSFT) on 8/21/2026.
Sold $1,001 – $15,000 in shares of Veralto (NYSE:VLTO) on 8/21/2026.
Sold $15,001 – $50,000 in shares of Honeywell Aerospace (NASDAQ:HONA) on 8/19/2026.
Sold $1,001 – $15,000 in shares of Colgate-Palmolive (NYSE:CL) on 8/19/2026.
Sold $1,001 – $15,000 in shares of Biogen (NASDAQ:BIIB) on 8/18/2026.
Sold $1,001 – $15,000 in shares of Anheuser-Busch InBev SA/NV (NYSE:BUD) on 8/18/2026.

Medtronic Stock Performance

NYSE:MDT opened at $92.10 on Thursday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13. The stock has a market capitalization of $117.89 billion, a PE ratio of 22.69, a P/E/G ratio of 2.15 and a beta of 0.56. Medtronic PLC has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The company has a fifty day moving average of $86.27 and a two-hundred day moving average of $85.35.

Medtronic (NYSE:MDT – Get Free Report) last announced its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.06. The business had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.89%. The company’s revenue for the quarter was up 13.7% compared to the same quarter last year. During the same quarter last year, the business earned $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, research analysts forecast that Medtronic PLC will post 5.96 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be given a dividend of $0.72 per share. The ex-dividend date is Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a yield of 3.1%. Medtronic’s dividend payout ratio is currently 70.94%.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Skip Kiil sold 4,189 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the sale, the executive vice president owned 37,227 shares in the company, valued at $2,994,539.88. The trade was a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.27% of the company’s stock.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

Positive Sentiment: Beat-and-raise results: Medtronic reported fiscal Q1 FY2027 adjusted EPS of $1.45, ahead of the $1.39 consensus, while revenue increased 13.7% year over year to $9.76 billion, exceeding estimates. Growth was broad-based, led by cardiovascular sales, with additional contributions from neuroscience, medical surgery and diabetes. Medtronic Q1 Earnings and Revenues Top Estimates
Positive Sentiment: Higher fiscal-year outlook: Management raised fiscal 2027 organic revenue-growth guidance to 7.25%-7.75% and adjusted EPS guidance to $5.94-$6.00. Analysts viewed the update as evidence that growth is accelerating across the portfolio, although the outlook benefited from an extra fiscal week in the quarter. Medtronic Begins Fiscal 2027 With a Beat-and-Raise
Positive Sentiment: Robotics and heart-tech expansion: Medtronic committed approximately $700 million to a strategic partnership with Cornerstone Robotics, gaining rights to distribute its Sentire surgical system in select markets outside the United States. It also plans to invest up to $80 million in Pi-Cardia to support complex transcatheter aortic-valve replacement procedures. These deals broaden Medtronic’s growth platforms alongside its Hugo robotic system. Medtronic Announces Strategic Partnership with Cornerstone Robotics
Positive Sentiment: Supportive analyst views and trading activity: RBC reaffirmed an Outperform rating with a $118 target, while BTIG raised its target to $100 and kept a Buy rating. Unusually heavy call-option activity also indicates increased speculative interest following the earnings report. Medtronic Analysts Raise Their Forecasts
Neutral Sentiment: Stifel raised its price target to $95 but retained a Hold rating, and Baird lifted its target to $100 while maintaining Neutral, signaling that valuation and execution remain considerations despite the improved outlook. Medtronic Shares Gap Up on Better-Than-Expected Earnings

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Rothschild & Co Redburn lowered their price objective on Medtronic from $111.00 to $106.00 and set a “buy” rating on the stock in a report on Friday, June 5th. JPMorgan Chase & Co. reduced their target price on Medtronic from $100.00 to $86.00 and set a “neutral” rating for the company in a report on Thursday, June 4th. TD Cowen raised their target price on Medtronic from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Friday, August 28th. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a research note on Monday, August 10th. Finally, Mizuho set a $115.00 price target on Medtronic in a research report on Wednesday. Nineteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and an average price target of $102.96.

Read Our Latest Analysis on Medtronic

Institutional Trading of Medtronic

A number of hedge funds have recently bought and sold shares of the business. Madison Asset Management LLC grew its position in Medtronic by 15.0% in the fourth quarter. Madison Asset Management LLC now owns 195,216 shares of the medical technology company’s stock worth $18,752,000 after acquiring an additional 25,527 shares during the period. First Eagle Investment Management LLC lifted its position in Medtronic by 0.4% in the fourth quarter. First Eagle Investment Management LLC now owns 9,775,234 shares of the medical technology company’s stock valued at $939,009,000 after buying an additional 40,196 shares during the last quarter. Gradient Investments LLC increased its position in shares of Medtronic by 3.9% during the second quarter. Gradient Investments LLC now owns 496,513 shares of the medical technology company’s stock valued at $38,842,000 after acquiring an additional 18,509 shares during the last quarter. Czech National Bank raised its stake in shares of Medtronic by 4.7% in the 2nd quarter. Czech National Bank now owns 365,443 shares of the medical technology company’s stock valued at $28,589,000 after acquiring an additional 16,292 shares during the period. Finally, Cerity Partners LLC raised its stake in shares of Medtronic by 12.7% in the 4th quarter. Cerity Partners LLC now owns 791,015 shares of the medical technology company’s stock valued at $75,988,000 after acquiring an additional 89,111 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Medtronic

(Get Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).